News

January 3, 2019Compass Therapeutics to Present at J.P. Morgan Healthcare Conference
December 19, 2018Compass Therapeutics Expands Leadership Team with Appointments of Chief Medical Officer and Chief Financial Officer
November 26, 2018Compass Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 6, 2018Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
October 2, 2018FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company
July 12, 2018Compass Therapeutics Completes $132 Million Series A Financing to Advance Next-Generation Antibody-Based Therapeutics into the Clinic

Posters and Publications

November 10, 2018 | SITC 2018
CTX-471, a novel agonistic antibody targeting CD137, eradicates very large tumors by selectively reprogramming the tumor microenvironment without causing hepatic toxicity

November 10, 2018 | SITC 2018
CTX-471, a novel agonistic antibody targeting CD137, enhances the anti-tumor activity of tumor antigen-targeted antibodies and immune checkpoint inhibitors when used in combination

November 10, 2018 | SITC 2018
A novel class of NK cell engagers overcomes CD16A deficiency